Published in Patient Care Law Weekly, July 16th, 2006
BioVeris adopted FASB Interpretation No. 46, "Consolidation of Variable Interest Entities" (FIN 46), as of March 31, 2004 based on a determination that Meso Scale Diagnostics, LLC. (MSD) qualified as a variable interest entity with the company as the primary beneficiary. Accordingly, beginning as of March 31, 2004, the company consolidated the financial information of MSD in its financial statements. In August 2004, the company and MSD entered into a settlement agreement that resolved...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Patient Care Law Weekly